Board of Directors, at its meeting held on today, consider and allotted 22,44,000 Equity Shares pursuant to the conversion of warrants the 22,44,000 convertible warrants (out of a total ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dipna Pharmachem's Board, at its meeting on 29th November 2025, approved the allotment of 22,44,000 fully paid-up equity shares to non-promoter allottees Mr. Ashok Dilipkumar Jain and Ms. Kajal Ashok Jain upon conversion of an equivalent number of convertible warrants. The shares were issued at Rs. 13.05 each (face value Rs. 10 plus Rs. 3.05 premium), bringing in Rs. 2.19 crore as the remaining 75% balance consideration. With this conversion, the company's paid-up equity share capital rose from Rs. 24.05 crore (2.40 crore shares) to Rs. 26.29 crore (2.63 crore shares). These warrant conversions are part of a larger pool of 5,80,32,500 convertible warrants originally allotted in September 2025, of which 1,65,69,000 warrants remain unconverted with the same allottees.
This is a routine partial conversion of previously issued warrants that increases the share count by about 9.3%, mildly diluting existing shareholders but also adding Rs. 2.19 crore to the company's funds. Since both allottees are non-promoters and had pre-committed to the warrants, the move is largely procedural and unlikely to materially impact the stock price.